DIAGNOS Announces Amendment to Convertible Debentures

BROSSARD, Quebec, March 31, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues using advanced technology based on Artificial Intelligence (AI), announces that it intends to amend the terms of an aggregate amount of $120,000 of unsecured convertible debentures (each a “Debenture”) issued as part of a private placement of units initially announced on March 28, 2022, as follows:

Read more at globenewswire.com